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a b s t r a c t 
Transformative cell and gene therapies have now launched worldwide, and many potentially curative cell 
and gene therapies are in development, offering the prospect of significant health gains for patients. Ac- 
cess to these therapies depend on decisions made by health technology assessment (HTA) and payer 
organizations. We sought to describe the emerging cell and gene therapies market access landscape by 
analyzing 17 US commercial payer medical policies, and HTA reports from five European countries and 
Canada. We found that some US health plans applied coverage restrictions more often than others (four 
plans applied restrictions in all decisions, while four plans applied restrictions in < 30% of decisions). The 
European and Canadian HTA bodies recommend access to fewer therapies than US health plans, reflecting 
a more stringent approach in the context of limited evidence and high scientific uncertainty that is com- 
monly associated with these treatments. Our findings suggest that patient access to approved cell and 
gene therapies is restricted in all regions studied, though the nature of these restrictions differs between 
US health plans and the European/Canada HTA recommendations. Payers, HTA groups, pharmaceutical 
companies, and other stakeholders should collaborate to more clearly define the “uncertainties” and de- 
velop market access policies that balance benefits of early access with ongoing data collection to close 
evidence gaps over time. 
© 2021 The Authors. Published by Elsevier B.V. 
This is an open access article under the CC BY license ( http://creativecommons.org/licenses/by/4.0/ ) 
1. Introduction 
Over the past several years, transformative cell and gene ther- 
apies have launched worldwide, and hundreds of potentially cura- 
tive cell and gene therapies are in development, offering the poten- 
tial of significant health gains for patients suffering from chronic or 
life-threatening conditions with limited existing treatment options. 
Regulators have accelerated the review and approval of these ther- 
apies, in some cases with relatively limited evidence, and most of 
∗ Corresponding author at: Novartis Gene Therapies, Inc. Bannockburn, IL, USA. 
E-mail address: omar.dabbous@novartis.com (O. Dabbous). 
these products have secured some degree of market access from 
payers. Yet, despite their potential value for patients and society, 
significant challenges and uncertainty related to value assessment, 
reimbursement, and payment models remain. 
While potential patient benefits are recognized by payers, they 
are coupled with concerns over the limited evidence of benefits 
and safety available at the time of approval. Specific contributors 
to this uncertainty include the use of single-arm trials and histor- 
ical cohorts for comparison [1] , inappropriate comparators, ques- 
tions about the durability of effect [2] , and limited knowledge 
of effectiveness in larger patient cohorts. Indeed, these concerns 
have been described previously and were summarized in a sys- 
https://doi.org/10.1016/j.healthpol.2021.10.003 
0168-8510/© 2021 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license ( http://creativecommons.org/licenses/by/4.0/ ) 
Please cite this article as: S. Tunis, E. Hanna, P.J. Neumann et al., Variation in market access decisions for cell and gene therapies across 
the United States, Canada, and Europe, Health policy, https://doi.org/10.1016/j.healthpol.2021.10.003 
S. Tunis, E. Hanna, P.J. Neumann et al. Health policy xxx (xxxx) xxx 
ARTICLE IN PRESS 
JID: HEAP [m5G; November 8, 2021;17:5 ] 
tematic overview of market access conditions for cell therapies in 
France, which found that a greater number of publications criti- 
cized uncertainty around the magnitude and duration of effect of 
regenerative therapies and precision medicines (54% of products in 
these categories in more than 60% of heath technology assessments 
[HTAs] in the set) compared with rare disease and non-precision 
oncology agents [3] . In addition, concerns over per patient and 
aggregate cost of these treatments are widely expressed, includ- 
ing worries about the cumulative financial impact on health care 
budgets of multiple gene therapies [ 1 , 4 ] and overall affordability 
[ 1 . 5 , 6 ]. 
Patient access to these therapies ultimately depends on deci- 
sions made by HTA and payer organizations. Payers in some coun- 
tries have begun experimenting with mechanisms to mitigate both 
the high uncertainty at the time of product launch as well as con- 
cerns about affordability using managed entry agreements (e.g., 
outcomes-based agreements, installment payments) [ 5 , 7 , 8 ]. A clear 
understanding of HTA and payers’ experience in reimbursing avail- 
able cell and gene therapies will inform ongoing discussions and 
ultimately help to define optimal approaches for assessment and 
reimbursement of the numerous cell and gene therapies expected 
to reach the market in the next 5–10 years. The comparison of 
US policies with those in other countries offers some useful in- 
sights into the nuances of policies, and how they might be ad- 
justed to ensure that market access decisions reflect the underlying 
evidence. 
This article describes the market access landscape of emerg- 
ing cell and gene therapies by analyzing commercial payer medical 
policies from 17 US payers and HTA reports from 6 other countries 
(EU5 [France, Germany, Spain, Italy, the United Kingdom (UK)], and 
Canada). We also summarized and compared HTA recommenda- 
tions and reimbursement policies and practices for currently ap- 
proved gene and cell therapies. Examining HTA and payer poli- 
cies also documents patterns of restrictions on coverage and al- 
lows us to probe the rationales underlying those restrictions. Un- 
derstanding the market access landscape provides insights about 
activities necessary to ensure that patients have timely access to 
therapies that are likely to provide clinical benefits. More specifi- 
cally, insights into payer/HTA approaches could inform clinical de- 
velopment strategies, study design decisions, and commercializa- 
tion approaches. In addition, regular, early meetings between HTA 
agencies and manufacturers provide an opportunity to manage ex- 
pectations around evidence and to address pre- and post-market 
data collection. 
2. Methods 
2.1. US commercial payer medical policies 
We used the Tufts Medical Center Specialty Drug Evidence and 
Coverage (SPEC) Database to examine how US commercial health 
plans cover cell and gene therapies [9] . SPEC includes specialty 
product (drugs, biologics, and cell and gene therapies) coverage de- 
cisions issued by 17 of the 20 largest US commercial health plans 
(in terms of premiums earned) — information that represents the 
majority of the country’s largest payers in terms of covered lives 
( ∼60% of commercially covered lives). Of the three excluded plans, 
two focus exclusively on public payers (Medicare or Medicaid pop- 
ulations), and the third does not make its coverage decisions pub- 
licly available [10] . SPEC includes six national and 11 regional com- 
mercial health care payers. The database details how the included 
health plans cover specialty products for their enrollees (including 
any restrictions or conditions on coverage), and the evidence that 
the plans cite in their coverage policies. 
SPEC includes coverage decisions for four cellular therapies (ti- 
sagenlecleucel, axicabtagene ciloleucel, sipuleucel-T, and talimo- 
gene laherparepvec [t-vec]) and two gene therapies (onasemno- 
gene abeparvovec and voretigene neparvovec-rzyl). Coverage de- 
cisions included in this analysis were current as of April 
2020. 
We compared health plan coverage policies with the Food and 
Drug Administration (FDA)-approved label. We categorized any 
coverage or reimbursement restrictions that plans applied in their 
decisions as 
• Patient subgroup restrictions (a requirement for patients to 
meet certain clinical criteria beyond the parameters of the FDA 
label indication [e.g., severity or duration of symptoms]), 
• Step therapy protocols (a requirement for patients to first fail 
an alternative therapy), or 
• Site-of-care restrictions (a requirement for the treatment to be 
administered in a particular facility). 
We also reported whether the coverage policy included a re- 
quirement for a certain type of physician (e.g., an oncologist) to 
prescribe the product. Specific rationale for clinical restrictions 
or information on non-clinical restrictions, such as price reduc- 
tions and managed entry agreements, are not included in the SPEC 
database. This information was available in HTA reports from EU5 
and Canada, as described below. 
2.2. HTA reports from EU5 and Canada 
A search was conducted in December 2019 to identify cell and 
gene therapies approved in Europe [11] and Canada [12] . Available 
HTA reports for these therapies were extracted from EU5 (France, 
Italy, Spain, the UK [England/Scotland], Germany) and Canada HTA 
websites: 1) France: French health authority (HAS), 2) Germany: 
Federal Joint Committee (G-BA) and Institute for Quality and Effi- 
ciency in Health Care (IQWIG), 3) UK England: the National Insti- 
tute for Health and Care Excellence (NICE), Scotland: the Scottish 
Medicines Consortium (SMC), 4) Italy: the Italian Medicines Agency 
(AIFA), 5) Spain: Agencia de Evaluación de Tecnologias Sanitarias 
(AETS), 6) Canada: Canadian Agency for Drugs and Technologies in 
Health (CADTH). 
For each HTA report, clinical restrictions were categorized as 
defined above for US medical policies. When available, we also ex- 
tracted information on the rationale for positive coverage recom- 
mendations, any restrictions, non-coverage advice, and non-clinical 
restrictions such as price reductions and managed entry agree- 
ments. Restrictions for European and Canadian HTA reports were 
defined relative to the EMA or Health Canada marketing authoriza- 
tions, respectively. 
3. Results 
3.1. US commercial payer medical policies 
The included health plans issued 109 coverage policies for the 
six cell and gene therapies noted in the Methods section. Over- 
all, these plans applied coverage restrictions in 64% (70/110) of 
their decisions ( Fig. 1 ). Plans most generously covered t-vec, with 
67% (8/12) covering the product in accordance with the FDA la- 
bel. Health plans were most restrictive with coverage of voretigene 
neparvovec-rzyl and onasemnogene abeparvovec, applying restric- 
tions in 100% of coverage decisions (17/17 and 16/16, respectively). 
Some health plans applied coverage restrictions in their deci- 
sions more often than others. Four plans applied restrictions in 
100% of their decisions, while four plans applied restrictions in 
< 30% of their decisions. 
Of restricted coverage decisions ( n = 70), plans applied patient 
subgroup restrictions and site of care restrictions in 89% and 17% of 
decisions, respectively. No plans applied step therapy protocols in 
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Fig. 1. Coverage restrictions: US commercial health plans # of coverage policies in parentheses — maximum of 17 policies. 
their decisions. Health plans included prescriber requirements in 
28% (31/110) of decisions. Health plans applied patient subgroup 
restrictions more consistently in their coverage decisions for some 
products than others. For instance, in their decisions for axicab- 
tagene ciloleucel, six plans applied the same patient subgroup re- 
striction by limiting access only to patients with an Eastern Co- 
operative Oncology Group performance status (a measure of pa- 
tients’ general well-being and activities of daily life) of ≤1. In con- 
trast, in their decisions for onasemnogene abeparvovec, 15 plans 
required that patients have a particular number of copies of the 
SMN2 gene (an indirect indicator of disease severity), but details of 
the requirement varied: one plan required two copies of the SMN2 
gene; two plans required one or two copies; one plan required two 
or three copies; and 11 plans required three or fewer copies. As 
noted in the Methods section, the SPEC database does not include 
information on non-clinical restrictions such as price reductions or 
managed entry agreements. Medical policies by US payers provide 
little detail about the specific rationale for clinical restrictions in 
these policies, and it is therefore not possible to make a direct link 
between the review of scientific evidence and the clinical restric- 
tions included in these medical policies. General comments about 
the limitations of clinical studies are mentioned in some medical 
policies, but not explicitly tied to the clinical restrictions in those 
policies. 
3.2. EU5 and Canada HTA reports 
By December 2019, 10 cell and gene therapies had been granted 
a centralized marketing authorization (MA) in the European Union; 
three MAs were later withdrawn by the applicant for commercial 
reasons. Thirty-five HTA opinions were identified from the HTA 
agencies’ official websites. Of the 10 products and 11 indications, 
G-BA reviewed 10 indications, HAS and NICE 8, AIFA 5, and other 
HTA agencies < 5. HTA reports from Canada were available for the 
two tisagenlecleucel indications. Tisagenlecleucel and axicabtagene 
ciloleucel were reviewed by most agencies, while other products 
were reviewed by < 50% of HTA agencies. 
After the cutoff date for this review, onasemnogene abepar- 
vovec was approved in Europe, but no HTA report was available 
at the time of manuscript preparation. In addition, the G-BA has 
recently issued a review of betibeglogene autotemcel (autologous 
CD34 + cells encoding βA-T87Q -globin gene). Results were updated 
accordingly. 
3.2.1. Clinical reimbursement restrictions 
Coverage restrictions based on clinical or patient criteria were 
issued in only three cases in Europe ( Fig. 2 ). T-vec received 
EMA authorization for the treatment of adults with unresectable 
melanoma that is regionally or distantly metastatic (Stage IIIB, IIIC, 
and IVM1a) with no bone, brain, lung, or other visceral disease. In 
England, it is reimbursed only for patients for whom immunother- 
apy was not suitable. 
Darvadstrocel (an allogenic stem cell therapy for treatment of 
complex perianal fistulas associated with Crohn’s disease) was ap- 
proved in Europe for the treatment of complex perianal fistulas in 
adult patients with non-active/mildly active luminal Crohn’s dis- 
ease, when fistulas have shown an inadequate response to at least 
one conventional or biologic therapy. In France, it is reimbursed for 
the subpopulation with complex, uncomplicated perianal fistulas, 
in combination with biologic therapy only in patients with quies- 
cent or non-active Crohn’s disease, with complex but not compli- 
cated perianal fistulas, and following an inadequate response (non- 
closure of fistula openings) to at least one biologic therapy in the 
previous 6 months. 
Betibeglogene autotemcel received EMA approval for the treat- 
ment of patients aged ≥12 years with transfusion-dependent β- 
thalassemia who do not have a β0/ β0 genotype, and for whom 
hematopoietic stem cell (HSC) transplantation is appropriate but a 
human leukocyte antigen-matched related HSC donor is not avail- 
able. In France, the population is limited to patients aged between 
12 and 35 years. 
Most cell and gene therapies are administered in specialized 
centers only. For example, the two CAR-T cell therapies — axicabta- 
gene ciloleucel and tisagenlecleucel — are restricted to specialized 
referral centers in the different countries. The autologous CD34 + 
for severe combined immunodeficiency related to adenosine deam- 
inase deficiency (Strimvelis®) has only one approved manufacturer 
because of its 6-hour shelf life. This treatment is currently only 
available at Hospital San Raffaele Telethon Institute for Gene Ther- 
apy in Milan. Patients need to travel to this hospital for treatment 
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Fig. 2. Coverage restrictions based on clinical or patient criteria: EU5 and Canada. W = marketing authorization withdrawn. 
∗Allogeneic T cells. † Autologous CD34 + cells transduced to express adenosine deaminase deficiency. 
with Strimvelis®. In France, administration of Luxturna® is autho- 
rized in just one center to date. 
3.2.2. Non-clinical reimbursement restrictions 
In the EU5 and Canada, non-clinical restrictions, specifically 
price reductions and managed access agreements, were identified 
in several countries ( Table 1 ). In England, among the seven cell 
and gene therapies for which HTA reports were available, NICE has 
recommended reimbursement of two cell and gene therapies with 
negotiated price reductions called patient access schemes, and two 
CAR-T cell therapies (tisagenlecleucel and axicabtagene ciloleucel) 
were funded through the Cancer Drugs Fund, with requirements 
for additional data collection and future review of the incremen- 
tal cost-effectiveness ratio in light of newly collected data. In Italy, 
AIFA has recommended four cell and gene therapies with managed 
entry agreements. In Canada, a price reduction has been negotiated 
for tisagenlecleucel and voretigene neparvovec. 
3.2.3. Rationale 
HTA reports often provide a rationale for decisions to limit ac- 
cess, with scientific uncertainty typically listed as the key reason. 
Single-arm study, short duration, and indirect comparison were re- 
ported as major sources of effectiveness uncertainty in 30–70% of 
reports. These HTA reports do not generally provide a specific ex- 
planation about the link between individual types of uncertainty 
and the specific clinical or non-clinical restrictions recommended. 
4. Discussion 
US health plans have applied restrictions in approximately 67% 
of their cell and gene therapy coverage policies. This suggests that 
US plans are substantially more restrictive in their coverage of 
cell and gene therapies compared with other orphan products, for 
which coverage is restricted in about 30% of health plan policies 
[13] . Given their high price, it is perhaps not surprising that health 
plans apply restrictions to the coverage of cell and gene therapies. 
Previous studies have shown that US health plans apply coverage 
restrictions more often to therapies with higher annual costs [9] . 
It is notable, however, that the frequency of coverage restrictions 
varied across US payers. We found that some health plans applied 
coverage restrictions more often than others, and that when health 
plans did apply restrictions, they did so inconsistently. 
This variation is important because US residents who are en- 
rolled in different health plans will not have equal access to these 
therapies, even when the clinical circumstances are identical. For 
instance, an SMA patient with three copies of the SMN2 gene 
would be ineligible for treatment with onasemnogene abeparvovec 
if they were enrolled in three health plans in our sample, but 
would be eligible if enrolled in the other plans. This variation is 
also important for physicians, as it means that they must tailor in- 
dividual treatment decisions not only to their patients’ clinical pre- 
sentation, but also to their insurance coverage. However, because 
most commercial health plans are provided through employers, in- 
dividual consumers may have limited ability to select health plans 
that cover these therapies. 
Medical policy reports from US payers do not provide a detailed 
explanation of the evidentiary basis of the restrictions in these 
policies, unlike the situation with HTA reports from the EU5 and 
Canada. It is therefore not possible to understand the scientific ra- 
tionale for most coverage restrictions in US payer policies, which 
leaves questions unanswered about the reasons for diverging from 
the scientific basis reflected in the clinical indications approved by 
the FDA. 
It is possible that the variation in these restrictions reflects the 
uncertainty regarding clinical benefits of these products, or that 
the restrictions reflect concerns about the cost of these therapies. 
The US policies do not describe which of those concerns, or pos- 
sibly others, are the basis for the coverage restrictions. In gen- 
eral, factors that support access and reasons for restricted access 
are available in many but not all ex-US HTA reports. HTA agen- 
cies should explain their specific considerations for arriving at final 
recommendations. This has been common practice in US Medicare 
coverage decisions for approximately 20 years [14] . 
This study suggests that EU5 and Canadian HTA bodies recom- 
mend access to fewer cell and gene therapies than US health plans, 
which may reflect a more stringent approach in the context of 
limited evidence and high scientific uncertainty that is commonly 
associated with this class of therapies. In contrast, when cover- 
age is recommended, it is typically consistent with the criteria in- 
cluded in regulatory approvals, with only a few exceptions where 
HTA bodies applied restrictions beyond the regulatory label. The 
EU5 and Canadian HTA bodies make market access recommenda- 
tions reflecting scientific evidence that is appraised according to 
explicit HTA decision analytic frameworks [15] . Specifically, most 
HTA agencies continue to rely heavily on evidence from higher 
quality studies, such as randomized controlled trials, in their as- 
sessments of benefits, risks, and value [16] . 
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As noted, the evidence available for cell and gene therapy prod- 
ucts at the time of approval is often less robust than for the classes 
of therapies with which HTA agencies are familiar. For example, 
in France, HAS will only accept subgroup analyses that have been 
pre-specified, and considers secondary endpoints only if the sta- 
tistical analysis adjusts for multiple testing. In both France and 
Germany, HAS and G-BA often reject indirect treatment compar- 
isons despite existing European guidelines that support their use 
[17] . Similarly, HAS and G-BA consider single-arm trials with his- 
torical controls to represent low-grade evidence, and inadequate to 
demonstrate superiority over current standard of care. While UK 
HTA bodies are, in general, more receptive to indirect comparison 
and historical controls, their recommendations still reflect the view 
that such study designs result in high uncertainty regarding bene- 
fits and risks, and make cost-effectiveness findings more uncertain. 
This uncertainty is reflected in the variety of novel payment mech- 
anisms, such as requirements to collect additional data and price 
discounts. 
While HTA groups and payers have clearly expressed concerns 
with the high degree of scientific uncertainty at the time of reg- 
ulatory approval, strategies to address these concerns are still de- 
veloping. Given that restrictions in coverage policies and HTA rec- 
ommendations are often influenced by residual uncertainty at the 
time of product approval, mechanisms to promote the generation 
of additional evidence to reduce uncertainty could be considered 
as an alternative to restrictions. 
Outside the US, there is increasing experimentation with man- 
aged entry agreements as a mechanism to promote further ev- 
idence generation. However, there is not yet a significant body 
of experience to determine the impact of these approaches on 
patient outcomes and/or financial consequences. Managed entry 
agreements are used with greater frequency, but usually involve 
substantial price concessions in addition to data collection com- 
mitments. 
Some experience from EU countries not included in this study 
provides additional examples of experimentation with payment 
models for cell and gene therapies. For example, in Sweden, 
Tandvårds- och läkemedelsförmånsverket (the national pricing and 
reimbursement authority) and the NT-council, (representative for 
the regions and the health care providers) have started working on 
ways to implement innovative payment models for cell and gene 
therapies. The purpose is to explore if innovative payment models 
can overcome both the uncertainty barrier and the budget barrier 
[18] . 
Outcomes-based agreements are being explored in the US as an 
approach to pay the full value-based price at the time of launch, 
with manufacturers at risk of paying rebates if longer-term out- 
come expectations are not met. These have not yet spread widely 
to US payers because of challenges related to the operational bur- 
den as well as limited availability of meaningful outcome measures 
to which these agreements should be linked. 
Effort s are also underway to develop the infrastructure that can 
efficiently gather high-quality, long-term, real-world data on these 
interventions [19] . New approaches to longitudinal data collection 
have the potential to reassure payers and regulators about long- 
term benefits and risks; however, these therapies may be replaced 
by newer alternatives within five years, raising doubts about the 
practical utility of these data. 
Finally, uncertainty at the time of product launch and the high 
cost of these products have led public payers in many countries to 
negotiate price discounts as an element of market access agree- 
ment. Because these agreements between drug companies and 
payers are confidential, we do not know if these agreements dif- 
fer by jurisdiction, or if the magnitude of the price reduction is 
linked to any other managed entry agreements or novel payment 
mechanisms. 
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5. Limitations 
Our analysis includes all currently approved cell and gene ther- 
apies. However, the limited number of such therapies approved in 
Europe and Canada, and the relatively small number of HTA re- 
ports available, make it difficult to draw more concrete conclu- 
sions. The therapies reviewed represent a heterogeneous group, 
ranging from highly effective to those with limited additional ben- 
efit. In some cases, a well-established, conventional therapy is 
available, while in others there may be no existing treatment al- 
ternative. Despite these sources of variability, the type of evidence 
limitations observed in this report are likely to persist going for- 
ward, with future therapies being supported by single-arm studies, 
short-term trials, surrogate endpoints, and other limitations that 
have been well documented in the HTA literature. 
The comparisons between the US payer policies and HTA re- 
ports from the EU5 and Canada are hampered by differences be- 
tween payer policies and HTA reports. The US health plan policies 
state directly what the payers will cover, and under what circum- 
stances, while in the HTA reports from Europe and Canada, actual 
patient access will sometimes depend on how closely local pay- 
ers follow the recommendations from the national HTA body. This 
connection is strong in France, Germany, and the UK, and less so in 
Canada, Spain, and Italy, where there are regional payers with ac- 
tive policy-making functions. Therefore, it is possible that in some 
cases, additional restrictions may be imposed by local payers, go- 
ing beyond the official HTA recommendation. 
The analysis of US payer medical policies has several limita- 
tions. First, these findings may not be generalizable to other com- 
mercial health plans, or to public health care payers. Second, not 
all health plans issued a coverage policy for each cell and gene 
therapy in our sample. Third, we did not account for differences in 
the included health plans. For instance, some plans are larger than 
others, and some are national while others are regional. Fourth, we 
did not account for how often patients successfully appeal denied 
coverage. Finally, we did not evaluate whether market access poli- 
cies for cell/gene therapies differed in specific ways compared with 
policies for orphan therapies that are not cell/gene therapies. 
6. Conclusions 
Patients’ access to cell and gene therapies varies across health 
plans in the US as well as member states in Europe and Canada. 
Our findings suggest that US commercial health plans use their 
coverage policies as a tool to carefully manage the utilization of 
these therapies. In Europe, several countries made no decisions re- 
garding access for several gene therapies, and they remain unavail- 
able in those countries. 
These data and observations suggest that patient access to cell 
and gene therapies following regulatory approval is restricted in 
all geographic regions studied, although the nature of these restric- 
tions differs between the US health plans and the EU5/Canada HTA 
recommendations. The primary underlying reasons for access re- 
strictions in all regions appear to be scientific uncertainty at the 
time of approval, limited evidence, and the high cost of these ther- 
apies. 
Access to cell and gene therapies remains very heterogeneous 
for different payers and countries, despite all decision makers us- 
ing the same studies and evidence in their policy development 
processes. These differences are linked to the variable perspectives 
on policy development in the setting of higher than traditional sci- 
entific uncertainty. In some jurisdictions, this is being addressed 
with risk-sharing arrangements and other forms of managed entry 
agreements. 
It would be valuable to engage the HTA and payer commu- 
nities in continued discussions about how best to reduce uncer- 
tainty over time, while allowing patient access to promising, in- 
novative therapies, and avoiding barriers to access that are linked 
to the geographic location of the organization that is paying for 
the patient’s care. Within the limitations that inherently arise from 
the numerous, variable contextual factors affecting access deci- 
sions, payers, HTA groups, drug companies, and other stakehold- 
ers should work together to define the “uncertainties” more clearly, 
and collaboratively develop market access policy mechanisms that 
balance the benefits of early access with ongoing data collection 
that provides missing evidence over time. 
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